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A predominant number of diseases affecting women are related to female hormones. In
most of the cases, these diseases are reported to be associated with menstrual problems.
These diseases affect female reproductive organs such as the breast, uterus, and ovaries.
Estrogen is the main hormone responsible for the menstrual cycle, so irregular menstru-
ation is primarily due to a disturbance in estrogen levels. Estrogen imbalance leads to
various pathological conditions in premenopausal women, such as endometriosis, breast
cancer, colorectal cancer, prostate cancer, poly cysts, intrahepatic cholestasis of preg-
nancy, osteoporosis, cardiovascular diseases, obesity, etc. In this review, we discuss com-
mon drug targets and therapeutic strategies, including acupuncture and compounds of
natural origin, for the treatment of diseases caused by estrogen deficiency.tributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any me-
operly cited.
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110 A. Thakur et al.1. Introduction
Estrogen, the primary female hormone, is synthesized in
the theca interna of the female ovary and varies throughout
the menstrual cycle. Follicle-stimulating hormone (FSH)
also stimulates the production of estrogens by the gran-
ulosa cells of the ovarian follicles and corpora lutea [1,2].
Estrogens are also synthesized in small amount in the
breast, liver, adrenal glands, and fat cells. Estrogen is
found to be at its highest level at the end of the follicular
phase in a menstrual cycle, just before ovulation [3]. It
promotes secondary sexual characters in females, such as
breast development, and also helps maintain the thickening
of the endometrium and prepares the uterine lining for
implantation of the fertilized ovary [4,5]. Such estrogen
dominance can start early in a woman’s menstrual history.
Long-term exposure to estrogen has been associated with
the development of breast cancer. Estrogen may contribute
to the development of cancer in an estrogen receptor (ER)-
dependent or ER-independent manner [6,7]. The ER-
dependent mechanism states that estrogen primarily acts
on ER alpha, which is a transcription factor and mediates
DNA synthesis and cellular proliferation. While some cells
may use different mechanisms to metabolize and deacti-
vate different estrogens (estradiol and estrone) resulting in
the generation of an intermediate reactive oxygen species,
which may damage DNA and eventually lead to cancer [8].
Aromatase, which may be localized in breast cancer
tissue, endometriosis, and uterine fibroids, is responsible
for converting androgens (androstenedione and testos-
terone) into estrogens (estrone and estradiol), and for
promoting cancerous growth and proliferation [8,9]. These
conditions may be dependent on the rising and falling of
estrogen waves during each menstrual cycle [6]. Estrogen is
a hormone whose imbalance is responsible not only for
reproductive disorders, but also for different types of
cancer. It may also contribute toward the development of
lupus erythematosus, osteoporosis, Alzheimer’s disease,Figure 1 Androgen bound to enzymecardiovascular diseases, insulin resistance, and obesity
[6,10]. Estrogen is also considered to be a morphogen for
the uterus, ovary, mammary gland, prostate, lung, and
brain [11]. Recurrence in breast cancer after mastectomy
and recurrence of endometriosis after total hysterectomy
are not uncommon [12e14]. In such cancerous conditions,
estrogen deprivation becomes a key therapeutic approach
[15].2. Common drug targets in estrogen-
dependent conditions
Aromatase enzyme is responsible for the synthesis of es-
trogens through conversion of androgens into estrogens by a
process called aromatization [14,15]. This leads to an in-
crease in the rate of production of estrogen, which pro-
motes estrogen-dependent diseases. This enzyme is
expressed in high concentrations in the placenta and the
granular cells of ovarian follicles. This enzyme is also pre-
sent in several nonglandular tissues such as endometrial
tissue, breast cancer tissue, normal breast tissue, subcu-
taneous fat, muscle, liver, and brain [16]. It is an anticancer
target by compounds inhibiting the action of the enzyme in
postmenopausal women [13,17,18]. Estrogen-dependent
diseases can be treated more effectively with new third-
generation aromatase inhibitors. The third-generation
aromatase inhibitors are available in preparations such as
letrozole, anastrazole, vorazole, etc. [17,19]. Letrozole is
considered to be the most promising aromatase inhibitor, as
it has been studied that patients on letrozole have lower
plasma estrogen levels than those on other third-generation
agents [20] (Fig. 1).
ER antagonists bind to ERs and inhibit the action of es-
trogen. ERs are available as homodimers of alpha and beta
subunits (Fig. 2). ER alpha antagonist has shown resistance
in treating estrogen-dependent cancer for a prolonged
period of time [21]. Recent studies provide an importantaromatase at its active binding site.
Figure 2 Estrogen bound to estrogen receptor a at its active binding site.
Natural Estrogen Modulators 111interface to study the role of ER beta for estrogen-
dependent tumors [22]. Among these estrogen antago-
nists, ethinyl estradiol is used in preparations such as ovral-
L and novelon. Compounds of natural origin include
genistein, which may act on both ER alpha and ER beta
(Fig. 3). Commonly used drugs in this patient subgroup are
clomifene and zuclomifene, which have found greater
acceptance [23]. Clomifene and zuclomifene are widely
used estrogen antagonists that may control estrogen levels
during menstrual cycle.
Aryl hydrocarbon receptor (AhR) is a ligand-mediated
transcription factor [24]. The AhR pathway has beenFigure 3 Natural estrogen modulator (genistein) bounshown to interact with ERs. AhR may inhibit estrogen
signaling by the activation of AhR/aryl hydrocarbon nuclear
translocator heterodimer; by binding to an inhibitory
xenobiotic response element in ER target genes; by
silencing coactivators, i.e., aryl hydrocarbon nuclear
translocator; by increasing proteasomal degradation of ER;
and by altering estrogen synthesis or metabolism [24].
Several natural and synthetic agonists have been identified
for this receptor. The first agonist to be identified was a
synthetic one; thereafter, many natural ligands were
identified, including tryptophan, tetrapyrroles, and arach-
idonic acid [25]. Although the role of natural compoundsd to estrogen receptor a at its active binding site.
Table 1 Natural estrogen modulators.
1. Genistein Glycine max Isoflavone Genistein may act by binding to estrogen receptors (a & b). [36]
2. Daidzein G. max Daidzein competes with endogenous estrogens binding with
human recombinant estrogen receptor b & consequently
prevent their activity.
[38]
3. Equol G. max [36]
4. Luteolin Terminalia chebula Flavone Luteolin competes with endogenous estrogens binding with
human recombinant estrogen receptor b & consequently
prevent their activity.
[36]
5. Chrysin Passiflora caerulea, Passiflora
incarnata, Oroxylum indicum
Chrysin performs potent inhibition of aromatase with
IC50 of 2.6 mM.
[38]
6. Quercetin Various fruits, vegetables, & grains Quercetin interacts with Type II estrogen-binding sites & inhibits
cell proliferation.
[39]
7. Kaempferol Apples, grapefruit, tea These have been found to bind weakly to the human recombinant
estrogen receptor b, thus preventing cell proliferation
[37]
8. Apigenin Various fruits & vegetables High doses of apigenin block ERa mobility & transcriptional activity,
& induce degradation of ERa & its coactivator AIB1. However, it
may act via ERa-independent pathway as a kinase inhibitor.
[43]
9. 8-Prenyl
naringenin
Humulus lupulus Prenyl
flavonoid
It has been shown to reduce hot flushes by binding to both ERa
& ERb, but have higher affinity for ERa.
[40,41]
10. Naringenin Citrus paradisi Flavanone Studies have shown estrogen antagonist activity of this drug for
estrogen-sensitive cells. Have higher binding affinity for ERb
than for ERa.
[42]
11. Enterodiol They are classified as mammalian
phytoestrogens. They are synthesized by
bacteria in colon from pinoresinol,
lariciresinol, secoisolariciresinol, matairesinol,
hydroxymatairesinol, syringaresinol, & sesamin
mostly found in flax seed & sesame seed
Lignan Enterodiol acts as a protective agent for breast & prostate cancer
by inhibiting the aromatase enzyme, competing with estrogen for
Type II estrogen receptor, and inducing sex hormone-binding globulin.
[44e46]
12. Enterolactone
13. Resveratrol Skin of grapes, blueberries, raspberries, &
mulberries
Stilbenes Some studies states that it has higher transcriptional activity for
ERb than for ERa. Others state that it acts as an antagonist for ERa
but not for ERb. Some studies have shown resveratrol as an aromatase
inhibitor (IC50 2.5 mM) both by competitive & by noncompetitive
inhibition. Moreover, this drug has been shown to induce apoptosis
through AhR.
[35,47,48]
14. Indole-3-
carbinol
Cruciferous vegetables Indole
derivative
Studies have shown that this drug does not bind to ERa & ERb.
Rather, it triggers aryl hydrocarbon (AhR)-dependent degradation
of ERa. Thus, degradation of ERa plays a significant role in inhibiting
proliferation of estrogen-dependent tumor cells.
[49]
15. Ellagic acid Quercus alba, Quercus robur, Myriophyllum
spicatum, Phellinus linteus
Polyphenol Ellagic acid may act as a selective estrogen receptor modulator.
It possesses little action on ERa while potently antagonizing ERb.
[50]
16. Gallic acid Q alba, Q. robur, Caesalpinia mimosoides Phenolic acid Studies on gallic acid, a natural phenolic acid found in plants,
have shown that it possesses higher affinity for ERb with an
IC50 value of 100.3 mM.
[50]
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17. Punicic acid Punica granatum Poly
unsaturated
fatty acid
It has been shown to possess an estrogen-inhibiting activity,
with IC50 values of 7.2 mM & 8.8 mM at ERa & ERb, respectively.
[51]
18. Delphinidin-3-
glucoside
Blackcurrant, blueberry,
huckleberry, & bilberry leaves
Anthocyanin Studies have shown that this chemical moiety possesses better
binding affinity for ERb with an IC50 value of 63.2 mM. For ERb,
they have shown twofold more potency than gallic acid in spite
of similar hydroxylation pattern at ring B.
[52]
19. Pelargonidin-3-
glucoside
Pomegranate, strawberry, & purple corn Belonging to anthocyanin class, it has shown affinity for both ERs,
but higher affinity for ERa (IC50 Z 61.3 mM) than for ERb
(IC50 Z 93.0 mM).
[52]
20. Peonidin-3-
glucoside
Grapes & berries, red wine, red
onion, & purple corn
Studies have shown that this compound possesses affinity only
for ERa with an IC50 value of 64.4 mM.
[52]
21. Pelargonidin Pelargonium zonale, Anagallis monelli,
Philodendron bipinnatifidum
Aglycone
anthocyanin
Studies have shown that this aglycone anthocyanin possess
higher affinity for ERa as compared with ERb. SAR studies have
shown that the presence of a 2-OH group at B ring decreases
its affinity. Among all aglycone anthocyanins, pelargonidin has
shown the highest affinity for ERa with an IC50 value of 6.8 mM.
[53,54]
22. Delphinidin Plants in the genera Viola & Delphinium Delphinidin shows higher affinity for ERa than for ERb. Delphinidin
has been shown to possess second highest affinity, after
pelargonidin, for ERa with an IC50 value of 10.4 mM.
[54]
23. Cyanidin Different types of red berries Cyanidin possesses higher affinity for ERa as compared with
ERb, with an IC50 value of 10.4 mM for ERa.
[53,54]
24. Coumestrol Soybeans, Brussels sprouts, spinach,
& a variety of legumes
Coumestane Coumestrol has been shown to alleviate the conversion
of [3H]-estrone to [3H]-estradiol in vitro by inhibiting the
enzyme 17b-hydroxysteroid oxidoreductase Type 1 in a
dose-dependent manner.
[55]
AhR Z aryl hydrocarbon; ER Z estrogen receptor; IC50 Z Half maximal inhibitory concentration; SAR Z Structural-activity relationship.
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114 A. Thakur et al.targeting estrogen-dependent diseases is unclear, in some
studies phthalates have shown an interaction with ERs via
AhR [26]. Studies have shown that people treated with
drugs targeting estrogen-dependent diseases via AhR have
less chance of developing osteoporosis [27]. Further studies
on this receptor are needed, so that a potent AhR agonist
can be formulated for targeting estrogen-dependent dis-
eases [28].3. Natural compounds as potential
therapeutics
Flavonoids, primarily known for their antioxidant proper-
ties, have also shown antiestrogenic effect for the first time
in sheep, which leads to infertility [29]. Some studies have
shown that flavonoids may bind and activate ERs. Flavo-
noids have been classified into six classes: flavonols, fla-
vones, flavanols, flavanonols, flavanones, and isoflavones
[30]. Among all flavones, isoflavones have been shown to
possess the highest antiestrogenic activity. Flavanones and
flavones have been shown to possess better antiestrogenic
activity as compared with flavans. Studies have shown the
importance of 6, 7, or 4 hydroxy group in flavones for es-
trogenic activity [31].
Coumestanes are a class of natural phytoestrogen
found in a variety of food sources, including peas, beans,
sprouts, etc. Coumestanes have been shown to have
antiestrogenic propertiesdthey possess specific binding
affinity for ER beta. To explore their antiestrogenic
property, many chemical entities similar to coumestane
class were synthesized and isolated. Among them cou-
mesterol has shown more specific antiestrogenic affinity
for ER beta [32].
Lignans, one of the important phytoestrogens obtained
from dietary sources (flaxes and cereals), have been re-
ported to possess antitumor activity against estrogen-
dependent cancers. It is believed that lignans mimic es-
trogen and bind to ERs, thus preventing the action of
endogenous estrogen. Moreover, studies also state that
when phytoestrogens are consumed, the endogenous es-
trogen is flushed out of the body, adding to the anti-
estrogenic activity of phytoestrogens [33,34].
Stilbenes are diarylethylene hydrocarbons existing in
two possible isomers, cis and trans. Many stilbenoids are
present in plants, and between the two isoforms, trans
possess greater antiestrogenic activity. Many synthetic
drugs such as diethylstilbestrol, fosfestrol, and dienestrol
have been designed on the basis of the trans isoform. Some
natural stilbenes include pterostilbene and resveratrol
[35].
A list of estrogen-modulating natural compounds and
their mechanisms of action are listed in Table 1, while their
chemical structures are shown in Fig. 4.Figure 4 Structures of natural compounds with estrogen-
modulating properties.4. Acupuncture for estrogen-associated
conditions
Premenopause and menopause may be associated with
mood swings and minor memory deficit, which are associ-
ated with a low estrogen level. Although hormone
Natural Estrogen Modulators 115replacement therapy may improve the condition up to a
certain extent, there are other problems also [56]. Recent
reports have shown certain acupuncture protocol may treat
menopausal syndrome and subsequently improve memory
[58,59]. The treatment is also claimed to alter plasma
estradiol levels [57]. Acupuncture has also been shown to
improve learning and memory by increasing brain estrogen
levels in rats [58,59]. In a study comparing the effects of
acupuncture and estrogen on the frequency of hot flushes
suggest that electroacupuncture may significantly reduce
the frequency of hot flushes. Although estrogen therapy
may be more effective than acupuncture in reducing hot
flushes, acupuncture therapy has limited side effects as
compared with estrogen therapy [60]. Vasomotor symptoms
are common among the group of women suffering from
breast cancer who are undergoing antiestrogen therapy, so
it becomes extremely difficult to treat such a group of
patients. However, treatment of such a group of patients
for vasomotor symptoms associated with antiestrogen
therapy with acupuncture appears to be effective and safe
[61]. Repeated electroacupuncture stimulation at some
effective acupoints has also been reported to increase ER
expression and enhance estrogen levels in ovariectomized
animals, thus suggesting a long-term increase and normal-
ization of Hypothalamic-pituitary-adrenal (HPA) axis
dysfunction [62,63].
Patients on acupuncture therapy showed decreased
levels of FSH and luteinizing hormone in the serum, while
estradiol was increased. This in turn led to reduced anxiety,
and improved menstruation and perimenopausal symptoms.
The possible mechanism has been related to genes and
proteins associated with the PI3K (phosphoinositide 3-ki-
nase)/Akt/mTOR signaling pathway [64e66]. Han’s acu-
point nerve stimulator treatment could improve the clinical
pregnancy rate in patients with a decreased ovarian reserve
during in vitro fertilization and embryo transfer cycles by
increasing the antral follicle count and anti-Mu¨llerian hor-
mone levels and decreasing the estradiol level, FSH, and
FSH/luteinizing hormone ratio [67]. Polycystic ovary syn-
drome remains one of the most common causes of anov-
ulation in women of reproductive age, while nerve growth
factor has been associated with its pathogenesis. Electro-
acupuncture treatment has been shown to partly reverse
the nerve growth factor abundance, specifically in the
ovaries [68,69]. Acupuncture can suppress abnormal in-
crease of body weight and decrease of plasma estrogen and
estrin levels in a rat model of ovariectomy-induced osteo-
porosis [70,71]. In human studies, therapeutic effect of
warm needle moxibustion on osteoporosis has been shown
to be better than that of oral caltrate with vitamin D2
administration with a corresponding increase in estradiol
levels [72]. Acupuncture has also been shown to reduce
climacteric syndrome, associated with an increase in body
weight, by decreasing the estrogen level [73,74]. Evidence
shows that acupuncture is responsible for an increase in
ovarian granular cell layer P450 aromatase. P450 aromatase
is an enzyme that has a role in estrogen synthesis and
improved endometrial receptivity at the time of implanta-
tion [74,75]. Electroacupuncture of “Sanyinjiao” (SP6) and
“Guanyuan” (CV4) may upregulate uterine and ovarian es-
trogens in rats by affecting the hypothal-
amusepituitaryeovarian axis [76e78]. Thus, acupuncturemay have a significant therapeutic impact on estrogen- and
ER-associated diseases, which is required to be explored
further.5. Conclusion
Here, we review the effect of different natural estrogenic
modulators as well as acupuncture against these patho-
logical conditions. Acupuncture shows little adverse ef-
fects. Some of the discussed natural compounds are
approved by the United States Food and Drug Administra-
tion as therapeutic agents for other diseases and thus may
be readily used, while others, after appropriate toxicolog-
ical screening, may eventually develop into new thera-
peutics for estrogen-dependent diseases.Disclosure statement
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